Stock Insights: Joy Global, Gardner Denver, Biglari, Pfizer, Achillion April 23rd
Joy Global, Inc. (NASDAQ:JOY): Baird said Joy Global’s earnings and margins are at an inflection point citing an improved outlook for both in 2H 2012 and next year. The firm expects SGA reductions, vertical integration of its automotive division, and a reversal of weather efficiencies to help accelerate its recovery. Shares are Outperform rated with a $55 price target.
Gardner Denver Inc. (NYSE:GDI): Baird said earnings at Gardner Denver are showing signs of bottoming despite lowered guidance by management. The firm cotes encouraging order growth, upcoming stock buybacks, and relative valuation. Baird remains long-term buyers of the stock and maintains its Outperform rating and $82 price target.
Biglari Holdings Inc (NYSE:BH): BGB Securities believes shares of Biglari are extremely attractive for long-term investors and keeps a Buy rating on the name with a $500 price target.
Pfizer Inc. (NYSE:PFE): Leerink believes Pfizer’s divestiture of its Nutritionals business should be viewed as a positive since the sale price came in at the upper end of the firm’s expected range. However, Leerink views the risk/reward on shares of Pfizer as muted and reiterates a Market Perform rating on the stock.
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN): Wells Fargo reduced its valuation range on Achillion, citing less favorable safety and efficacy data for ’1625, and Achillion’s increasing reliance on a preclinical asset for an in-house, all-oral combination treatment. However, the firm still has a faovorable long-term outlook on Achillion and it maintains an Outperform rating on the stock.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.